ETPrime

Natco Pharma Share Price

  • 809.607.11 (0.89%)
  • Volume: 4,53,186
  • Closed
  • Last Updated On: 09 May, 2025, 03:59 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Natco Pharma Share Price
  • 809.607.11 (0.89%)
  • Volume: 4,53,186
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

HOLD

Mean Recos by
6 Analysts

0

2

1

2

1

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Natco Pharma share price insights

View All

  • Company witnessed QoQ revenue decline of 54.62%, which is lowest in the last 3 years. (Source: Consolidated Financials)

  • White Marubozu(s) was formed for Natco Pharma

  • Stock gave a 3 year return of 15.76% as compared to Nifty Midcap 100 which gave a return of 89.6%. (as of last trading session)

  • Company has spent less than 1% of its operating revenues towards interest expenses and 13.13% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Natco Pharma Ltd. share price moved up by 0.89% from its previous close of Rs 802.50. Natco Pharma Ltd. stock last traded price is 809.60

    Share PriceValue
    Today/Current/Last809.60
    Previous Day802.50803.00

InsightsNatco Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		7.77
    EPS - TTM
    (₹)    		104.13
    MCap
    (₹ Cr.)    		14,500.74
    Sectoral MCap Rank
    		32
    PB Ratio
    (x)    		2.46
    Div Yield
    (%)    		1.17
    Face Value
    (₹)    		2.00
    Beta

    Beta

    1 Month0.45
    3 Months0.54
    6 Months0.38
    1 Year0.70
    3 Years0.78
    		0.45
    VWAP
    (₹)    		799.60
    52W H/L
    (₹)
    1,639.00 / 726.80

    Natco Pharma Share Price Returns

    1 Day0.89%
    1 Week-3.75%
    1 Month8.45%
    3 Months-38.64%
    1 Year-16.5%
    3 Years9.5%
    5 Years31.73%

    ET Stock ScreenersTop Score Companies

    Check whether Natco Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Natco Pharma News & Analysis

    View all Natco Pharma Share News & Announcements

    Natco Pharma Share Recommendations

    Recent Recos

    HOLD

    Current

    Mean Recos by 6 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1145
    • OrganizationICICI Securities
    • ADD
    • Target₹1116
    • OrganizationGeojit Financial Services
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy1111
    Buy2332
    Hold1112
    Sell2222
    Strong Sell---1
    # Analysts6778
    View all Stock Recommendations

    Natco Pharma Financials

    • Insights

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 54.62%, which is lowest in the last 3 years. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 13.13% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income651.101,434.901,410.701,110.30795.60
      Total Income Growth (%)-54.621.7227.0639.56-25.00
      Total Expenses483.00612.60601.90626.50534.70
      Total Expenses Growth (%)-21.161.78-3.9317.17-13.34
      EBIT168.10822.30808.80483.80260.90
      EBIT Growth (%)-79.561.6767.1885.44-41.21
      Profit after Tax (PAT)133.00677.30668.50386.30212.70
      PAT Growth (%)-80.361.3273.0581.62-42.36
      EBIT Margin (%)25.8257.3157.3343.5732.79
      Net Profit Margin (%)20.4347.2047.3934.7926.73
      Basic EPS (₹)7.4337.8137.3221.5611.88
      Quarterly | AnnualDec 2024Sep 2024Jun 2024Mar 2024Dec 2023
      Total Income575.601,344.001,276.701,000.70654.80
      Total Income Growth (%)-57.175.2727.5852.83-31.45
      Total Expenses421.90544.10514.30563.70427.40
      Total Expenses Growth (%)-22.465.79-8.7631.89-19.08
      EBIT153.70799.90762.40437.00227.40
      EBIT Growth (%)-80.794.9274.4692.17-46.74
      Profit after Tax (PAT)124.90661.10636.30349.10192.00
      PAT Growth (%)-81.113.9082.2781.82-46.70
      EBIT Margin (%)26.7059.5259.7243.6734.73
      Net Profit Margin (%)21.7049.1949.8434.8929.32
      Basic EPS (₹)6.9736.9135.5319.4910.72
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue4,126.902,811.702,043.802,155.702,022.40
      Total Revenue Growth (%)46.7837.57-5.196.59-9.09
      Total Expenses2,453.401,949.801,841.601,576.101,453.70
      Total Expenses Growth (%)25.835.8816.858.423.84
      Profit after Tax (PAT)1,388.30715.30170.00440.90460.80
      PAT Growth (%)94.09320.76-61.44-4.32-28.49
      Operating Profit Margin (%)42.3332.3711.3028.8930.81
      Net Profit Margin (%)34.7126.428.7421.4824.06
      Basic EPS (₹)77.3439.189.3224.2025.33
      Quarterly | Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Revenue3,673.602,436.501,862.401,754.601,914.00
      Total Revenue Growth (%)50.7730.836.14-8.33-9.55
      Total Expenses2,118.301,665.801,706.501,362.401,330.90
      Total Expenses Growth (%)27.16-2.3825.262.374.90
      Profit after Tax (PAT)1,306.60637.10139.10309.50474.50
      PAT Growth (%)105.09358.02-55.06-34.77-28.87
      Operating Profit Margin (%)43.9833.149.5724.4033.72
      Net Profit Margin (%)36.6127.097.8618.7126.50
      Basic EPS (₹)72.7934.907.6316.9926.08

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets6,906.305,657.405,109.104,791.904,587.80
      Total Assets Growth (%)22.0810.736.624.456.62
      Total Liabilities1,053.20783.60845.50668.50803.10
      Total Liabilities Growth (%)34.41-7.3226.48-16.76-1.11
      Total Equity5,853.104,873.804,263.604,123.403,784.70
      Total Equity Growth (%)20.0914.313.408.958.41
      Current Ratio (x)4.144.393.524.453.39
      Total Debt to Equity (x)0.060.030.090.060.08
      Contingent Liabilities58.8022.1022.4028.0098.80
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Total Assets6,554.005,387.904,978.004,752.504,646.70
      Total Assets Growth (%)21.648.234.742.286.67
      Total Liabilities961.70685.90786.10661.40777.20
      Total Liabilities Growth (%)40.21-12.7518.85-14.90-1.98
      Total Equity5,592.304,702.004,191.904,091.103,869.50
      Total Equity Growth (%)18.9312.172.465.738.60
      Current Ratio (x)3.854.383.344.173.40
      Total Debt to Equity (x)0.060.030.090.060.08
      Contingent Liabilities58.8055.0052.3042.8098.80

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 1032.7 cr for investing activities which is an YoY increase of 116.45%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities1,211.60849.1046.50298.80417.30
      Net Cash used in Investing Activities-1,032.70-477.10-5.30-103.30-167.00
      Net Cash flow from Financing Activities-246.90-363.0034.80-185.70-250.80
      Net Cash Flow-61.5020.8085.306.00-8.50
      Closing Cash & Cash Equivalent70.40131.90111.1025.8019.80
      Closing Cash & Cash Equivalent Growth (%)-46.6318.72330.6230.30-30.04
      Total Debt/ CFO (x)0.300.198.690.890.76
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Net Cash flow from Operating Activities1,196.40784.4057.70183.50422.50
      Net Cash used in Investing Activities-960.50-436.60-92.50-3.20-165.00
      Net Cash flow from Financing Activities-237.30-346.8035.60-183.10-261.10
      Net Cash Flow-1.401.000.80-2.80-3.60
      Closing Cash & Cash Equivalent5.506.905.905.107.90
      Closing Cash & Cash Equivalent Growth (%)-20.2916.9515.69-35.44-31.30
      Total Debt/ CFO (x)0.300.206.741.390.74

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)23.7114.673.9810.6912.21
      Return on Capital Employed (%)28.5217.614.9913.8915.12
      Return on Assets (%)20.1012.643.329.2010.04
      Interest Coverage Ratio (x)97.8971.7420.4853.3732.09
      Asset Turnover Ratio (x)0.640.500.360.350.40
      Price to Earnings (x)12.2714.3981.3034.2520.00
      Price to Book (x)2.912.113.243.652.44
      EV/EBITDA (x)8.759.5238.6721.1913.73
      EBITDA Margin (%)47.0038.4218.6334.5836.03
      Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
      Return on Equity (%)23.3613.543.317.5612.26
      Return on Capital Employed (%)27.6916.173.919.5215.14
      Return on Assets (%)19.9311.822.796.5110.21
      Interest Coverage Ratio (x)120.12108.1623.1345.9029.31
      Asset Turnover Ratio (x)0.600.450.360.3538.52
      Price to Earnings (x)13.0416.16100.0048.7819.42
      Price to Book (x)3.052.193.303.682.38
      EV/EBITDA (x)9.4910.7945.8729.0213.50
      EBITDA Margin (%)48.8039.5617.4031.3639.20

    Financial InsightsNatco Pharma

    • Income (P&L)
    • Cash Flow

      • Quarterly Topline Performance

        Company witnessed QoQ revenue decline of 54.62%, which is lowest in the last 3 years. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 13.13% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 1032.7 cr for investing activities which is an YoY increase of 116.45%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Natco Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Natco Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Natco Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Natco Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Natco Pharma Technicals

    • Bullish / Bearish signals for Natco Pharma basis selected technical indicators and moving average crossovers.

      MACD Crossover

      Bearish signal on daily chart

      Appeared on: 8 May 2025

      Region: Negative

      Last 4 Sell Signals:13 Feb 2025
      Date10 days Gain/Loss %
      13 Feb 2025-20.18%
      27 Jan 2025-5.58%
      20 Dec 2024-4.26%
      18 Nov 2024-1.73%

      Average price decline of -3.77% within 10 days of Bearish signal in last 10 years

    • 42%
      Positive Movement since
      1st Jan 2005 on basis
      58%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic821.73833.87869.37798.37786.23762.87727.37

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR30.9633.4335.92

    Natco Pharma Peer Comparison

      • CHART
      • TABLE

      Insights

      • Stock Returns vs Nifty Midcap 100

        Stock gave a 3 year return of 15.76% as compared to Nifty Midcap 100 which gave a return of 89.6%. (as of last trading session)

      • Stock Returns vs Nifty Pharma

        Stock generated 15.76% return as compared to Nifty Pharma which gave investors 65.15% return over 3 year time period. (as of last trading session)

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Insights

          • Stock Returns vs Nifty Midcap 100

            Stock gave a 3 year return of 15.76% as compared to Nifty Midcap 100 which gave a return of 89.6%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 15.76% return as compared to Nifty Pharma which gave investors 65.15% return over 3 year time period. (as of last trading session)

          Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Natco Pharma7.772.4823.7128.5220.1023.9042.3334.7177.344.140.060.30
          Suven Pharma 98.2613.3814.6419.2413.322.8039.2928.5611.8011.820.020.11
          Syngene Int.49.825.2310.4912.617.3011.6918.6913.6212.351.640.030.10
          J B Chemicals37.088.1218.9025.4513.8317.5922.8415.8635.662.130.120.45
          Gland Pharma33.352.698.8512.507.2417.3020.4513.6346.904.040.040.32
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Wockhardt
          • Eris Lifesciences
          • Emcure Pharmaceuticals Ltd.
          • Alembic Pharma
          • Concord Biotech Ltd.

          Choose from Stocks

            See All Parameters

          Peers InsightsNatco Pharma

          • Stock Returns vs Nifty Midcap 100

            Stock gave a 3 year return of 15.76% as compared to Nifty Midcap 100 which gave a return of 89.6%. (as of last trading session)

          • Stock Returns vs Nifty Pharma

            Stock generated 15.76% return as compared to Nifty Pharma which gave investors 65.15% return over 3 year time period. (as of last trading session)

          Do you find these insights useful?

          • hate it

          • meh

          • love it

          Natco Pharma Shareholding Pattern

          • Loading...
            Showing Natco Pharma Shareholding as on Mar 2025
            CategoryMar 2025Dec 2024Sep 2024Jun 2024
            Promoters49.5649.6249.6249.71
            Pledge0.000.000.000.00
            FII17.4917.9417.5117.45
            DII5.475.586.757.85
            Mutual Funds1.851.922.372.67
            Others27.4826.8626.1224.99
          • Showing Shareholding as on Mar 2025
            CategoryNo. of SharesPercentage% Change QoQ
            Promoters8,87,70,27549.56 %-0.05
            Pledge00.00 %0.00
            FII3,13,34,27917.49 %-0.45
            DII98,09,5375.47 %-0.10
            MF33,19,0251.85 %-0.06
            Others4,91,95,77927.48 %0.62

          Natco Pharma MF Ownership

          MF Ownership as on 31 March 2025

          View all Mutual Fund Schemes
          Top Searches:
          Natco Pharma News Natco Pharma Quarterly Results Natco Pharma Dividend Natco Pharma Q1 ResultsNatco Pharma Q2 ResultsNatco Pharma Q3 ResultsNatco Pharma Q4 Results

          Natco Pharma Corporate Actions

          • Meeting DateAnnounced onPurposeDetails
            Feb 12, 2025Jan 30, 2025Board MeetingQuarterly Results & Interim Dividend
            Nov 12, 2024Oct 28, 2024Board MeetingQuarterly Results & Interim Dividend
            Aug 12, 2024Jul 26, 2024Board MeetingQuarterly Results & Interim Dividend
            May 27, 2024May 09, 2024Board MeetingAudited Results
            Feb 14, 2024Feb 02, 2024Board MeetingQuarterly Results & Interim Dividend
          • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
            Interim75%1.5Feb 18, 2025Feb 12, 2025
            Interim75%1.5Nov 27, 2024Nov 12, 2024
            Interim150%3.0Aug 23, 2024Aug 12, 2024
            Interim62%1.25Feb 26, 2024Feb 14, 2024
            Interim62%1.25Nov 24, 2023Nov 15, 2023
          • All TypesEx-DateRecord DateAnnounced onDetails
            SplitsNov 26, 2015Nov 28, 2015Aug 12, 2015Split: Old FV10.0| New FV:2.0

          About Natco Pharma

          Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 14,500.74 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Agrochemicals, Export Incentives, Other Operating Revenue, Scrap for the year ending 31-Mar-2024. Show More

          • Executives

          • Auditors

          • VC

            V C Nannapaneni

            Chairman & Ind.Director
            RN

            Rajeev Nannapaneni

            Director & CEO
            PS

            P S R K Prasad

            Director & Exe. VP (Corp. Engg. Services)
            AD

            A D M Chavali

            Independent Director
            Show More
          • B S R & Associates LLP

          Industry

          Pharma - Indian

          Key Indices Listed on

          Nifty Smallcap 100, Nifty 500, BSE 500, + 20 more

          Address

          NATCO House, Road # 2,Banjara Hills,Hyderabad, Telangana - 500034

          Contact

          investors@natcopharma.co.in

          http://www.natcopharma.co.in

          More Details

          FAQs about Natco Pharma share

          • 1. What is Natco Pharma share price and what are the returns for Natco Pharma share?
            Natco Pharma share price is Rs 809.60 as on 09 May, 2025, 03:59 PM IST. Natco Pharma share price is up by 0.89% based on previous share price of Rs 813.2. Natco Pharma share price trend:
            • Last 1 Month: Natco Pharma share price moved up by 8.45%
            • Last 12 Months: Natco Pharma share price moved down 16.50%
            • Last 3 Years: Natco Pharma Share price moved up by 9.50%
          • 2. Who's the chairman of Natco Pharma?
            V C Nannapaneni is the Chairman & Ind.Director of Natco Pharma
          • 3. What are the Natco Pharma quarterly results?
            On Consoldiated basis, Natco Pharma reported a total income and loss of Rs 651.10 Cr and Rs 133.00 respectively for quarter ending 2024-12-31. Total Income and profit for the year ending 2024-03-31 was Rs 4126.90 Cr and Rs 1388.30 Cr.
          • 4. How can I quickly analyze Natco Pharma stock?
            Key Metrics for Natco Pharma are:
            • PE Ratio of Natco Pharma is 7.77
            • Price/Sales ratio of Natco Pharma is 4.26
            • Price to Book ratio of Natco Pharma is 2.46
          • 5. What are the returns for Natco Pharma share?
            Return Performance of Natco Pharma Shares:
            • 1 Week: Natco Pharma share price moved down by 3.75%
            • 1 Month: Natco Pharma share price moved up by 8.45%
            • 6 Month: Natco Pharma share price moved down by 42.47%
          • 6. What is the CAGR of Natco Pharma?
            The CAGR of Natco Pharma is 18.15.
          • 7. Is Natco Pharma giving dividend?
            Natco Pharma Ltd. announced an equity dividend of 75% on a face value of 2.0 amounting to Rs 1.5 per share on 12 Feb 2025. The ex dividend date was 18 Feb 2025.
          • 8. What has been highest price of Natco Pharma share in last 52 weeks?
            Natco Pharma share price saw a 52 week high of Rs 1,639.00 and 52 week low of Rs 726.80.
          • 9. What is the PE & PB ratio of Natco Pharma?
            The PE ratio of Natco Pharma stands at 7.71, while the PB ratio is 2.45.
          • 10. Who owns Natco Pharma?
              • Promoter holding have gone down from 49.71 (30 Jun 2024) to 49.56 (31 Mar 2025)
              • Domestic Institutional Investors holding have gone down from 7.85 (30 Jun 2024) to 5.47 (31 Mar 2025)
              • Foreign Institutional Investors holding has gone up from 17.45 (30 Jun 2024) to 17.49 (31 Mar 2025)
              • Other investor holding has gone up from 24.99 (30 Jun 2024) to 27.48 (31 Mar 2025)
          • 11. Who is the CEO of Natco Pharma?
            Rajeev Nannapaneni is the Director & CEO of Natco Pharma
          • 12. Who are the peers for Natco Pharma in Pharmaceuticals sector?
            Within Pharmaceuticals sector Natco Pharma, Emcure Pharmaceuticals Ltd., Concord Biotech Ltd., Gland Pharma Ltd., J B Chemicals & Pharmaceuticals Ltd., Wockhardt Ltd., Eris Lifesciences Ltd., Neuland Laboratories Ltd., Suven Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd. and Syngene International Ltd. are usually compared together by investors for analysis.
          • 13. What is the market cap of Natco Pharma?
            Natco Pharma share has a market capitalization of Rs 14,500.74 Cr. Within Pharmaceuticals sector, it's market cap rank is 32.

          Trending in Markets

          Top Gainers As on 03:59 PM | 09 May 2025

          KPR Mill1,306.25
          276.30 (26.83%)
          R R Kabel1,234.80
          211.00 (20.61%)
          CCL Products723.35
          123.25 (20.54%)
          Welspun India146.90
          21.33 (16.99%)
          YES Bank20.02
          2.32 (13.11%)

          Top Losers As on 03:56 PM | 09 May 2025

          Jindal Saw201.68
          -43.75 (-17.83%)
          Sonata Software365.70
          -54.95 (-13.06%)
          Bank of Baroda220.09
          -28.52 (-11.47%)
          Godrej Properties2,000.50
          -248.80 (-11.06%)
          Indian Hotels718.75
          -81.75 (-10.21%)

          DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

          DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

          By using this site, you agree to the Terms of Service and Privacy Policy.

          Business News›Markets›Stocks›Stock Price Quotes›Natco Pharma Share Price
          The Economic Times
          BrowseCompanies: